Skip to contentGORDON CARL L — AMARIN CORP PLC insider: 395 transactions · InsiderLensGORDON CARL L
- Director at BIOCRYST PHARMACEUTICALS INC · on record since May 18, 2006
- Director at ArriVent Biopharma, Inc. · on record since Jan 31, 2024
- 10% owner at ArriVent Biopharma, Inc. · on record since Jan 31, 2024
- Director at MBX Biosciences, Inc. · on record since Sep 17, 2024
- 10% owner at MBX Biosciences, Inc. · on record since Sep 17, 2024
- Director at Venetian-1 Acquisition Corp. · on record since Nov 5, 2024
- Director at ACADIA PHARMACEUTICALS INC · on record since May 26, 2004
- Director at AMARIN CORP PLC · on record since Dec 30, 2010
- Director at COMPLETE GENOMICS INC · on record since Nov 10, 2010
- Director at Pacira Pharmaceuticals, Inc. · on record since Feb 10, 2011
- Director at ACCELERON PHARMA INC · on record since Sep 18, 2013
- Director at Cartesian Therapeutics, Inc. · on record since Jun 29, 2016
- 10% owner at Cartesian Therapeutics, Inc. · on record since Jun 29, 2016
- Director at Intellia Therapeutics, Inc. · on record since May 11, 2016
- 10% owner at Intellia Therapeutics, Inc. · on record since May 9, 2016
- Director at ACTELIS NETWORKS INC · on record since Nov 20, 2017
- 10% owner at ACTELIS NETWORKS INC · on record since Nov 20, 2017
- Director at ARMO BioSciences, Inc. · on record since Jan 30, 2018
- 10% owner at ARMO BioSciences, Inc. · on record since Jan 30, 2018
- Director at Alector, Inc. · on record since Feb 11, 2019
- 10% owner at Alector, Inc. · on record since Feb 11, 2019
- Director at Prevail Therapeutics Inc. · on record since Jun 26, 2019
- 10% owner at Prevail Therapeutics Inc. · on record since Jun 26, 2019
- Director at AXONYX INC · on record since Apr 24, 2019
- Director at SOUTHWALL TECHNOLOGIES INC /DE/ · on record since Sep 12, 2019
- 10% owner at SOUTHWALL TECHNOLOGIES INC /DE/ · on record since Sep 12, 2019
- Director at Oric Pharmaceuticals, Inc. · on record since Apr 28, 2020
- 10% owner at Oric Pharmaceuticals, Inc. · on record since Apr 28, 2020
- Director at COMPEX TECHNOLOGIES INC · on record since Jun 23, 2020
- 10% owner at COMPEX TECHNOLOGIES INC · on record since Jun 23, 2020
- Director at Keros Therapeutics, Inc. · on record since Apr 13, 2020
- Director at ACETO CORP · on record since Sep 17, 2020
- Director at Kinnate Biopharma Inc. · on record since Dec 9, 2020
- 10% owner at Kinnate Biopharma Inc. · on record since Dec 9, 2020
- Director at Terns Pharmaceuticals, Inc. · on record since Feb 26, 2021
- 10% owner at Terns Pharmaceuticals, Inc. · on record since Feb 26, 2021
- 10% owner at ACETO CORP · on record since Feb 18, 2021
- Director at Disc Medicine, Inc. · on record since Feb 10, 2021
- 10% owner at Disc Medicine, Inc. · on record since Feb 10, 2021
- Director at THERAVANCE INC · on record since Oct 14, 2021
- 10% owner at THERAVANCE INC · on record since Oct 14, 2021
- 10% owner at Chardan Healthcare Acquisition Corp. · on record since Mar 17, 2023
Insider trading activity of GORDON CARL L
- Transactions on record
- 395
- since Mar 10, 2004
- Open-market buys
- 82
- $177.3M
- Open-market sells
- 75
- $140.5M
- Companies traded
- 24
- last filing Jan 5, 2026
Figures computed from official regulatory filings — methodology.
Companies where GORDON CARL L has traded
- COMPEX TECHNOLOGIES INC16 tx · $33.6M · Jan 5, 2026
- Keros Therapeutics, Inc.15 tx · $20.8M · Dec 18, 2025
- MBX Biosciences, Inc.12 tx · $14M · Feb 19, 2025
- Venetian-1 Acquisition Corp.13 tx · $10M · Nov 5, 2024
- ACETO CORP36 tx · $19.1M · Aug 23, 2024
- Terns Pharmaceuticals, Inc.26 tx · $18.6M · Jul 17, 2024
- Chardan Healthcare Acquisition Corp.3 tx · $2.2M · May 20, 2024
- Kinnate Biopharma Inc.45 tx · $24.7M · Apr 5, 2024
- THERAVANCE INC24 tx · $14.5M · Feb 14, 2024
Track record of GORDON CARL L
Statistical track record
Free- Open-market buys
- 85
- Last buy
- Feb 18, 2025
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of GORDON CARL L
Co-insiders of GORDON CARL L
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
10 tx · $8M · Jan 31, 2024
OrbiMed Capital GP V LLCACETO CORP +3
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jan 5, 2026 | AwardD | 90,000 | 0.00 USD | $0 | SEC |
| Dec 18, 2025 | Other | -140,057 | 17.75 USD | $2.5M | SEC |
| Dec 18, 2025 | Other | -74,465 | 17.75 USD | $1.3M | SEC |
| Jun 6, 2025 | Award | 5,250 | 0.00 USD | $0 | SEC |
| Jun 6, 2025 | AwardD | 10,500 | 0.00 USD | $0 | SEC |
| Apr 11, 2025 | Sell | -3,571,428 | 1.59 USD | $5.7M | SEC |
| Feb 19, 2025 | Buy | 49,070 | 10.84 USD | $531.9K | SEC |
| Feb 19, 2025 | Buy | 29,540 | 9.85 USD | $291K | SEC |
| Feb 19, 2025 | Buy | 17,962 | 9.90 USD | $177.8K | SEC |
| Feb 19, 2025 | Buy | 94,100 | 10.84 USD | $1M | SEC |
| Feb 13, 2025 | AwardD | 40,000 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | OtherD | -215,146 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | Other | 323,916 | 3.20 USD | $1M | SEC |
| Nov 5, 2024 | OtherD | -323,916 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | Other | 230,753 | 3.60 USD | $830.7K | SEC |
| Nov 5, 2024 | Award | 479,736 | 4.00 USD | $1.9M | SEC |
| Nov 5, 2024 | Other | 389,078 | 3.60 USD | $1.4M | SEC |
| Nov 5, 2024 | Other | 215,146 | 3.20 USD | $688.5K | SEC |
| Nov 5, 2024 | OtherD | -230,753 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | OtherD | -74,613 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | OtherD | -389,078 | 0.00 USD | $0 | SEC |
| Nov 5, 2024 | Award | 155,120 | 4.00 USD | $620.5K | SEC |
| Nov 5, 2024 | Award | 808,894 | 4.00 USD | $3.2M | SEC |
| Nov 5, 2024 | Other | 74,613 | 3.60 USD | $268.6K | SEC |
| Sep 17, 2024 | Buy | 500,000 | 16.00 USD | $8M | SEC |